Heather Bresch

Heather Bresch 2015 Headshot

Heather Bresch is an American business executive known for her role in the pharmaceutical industry. She served as the CEO of Mylan, a global generic and specialty pharmaceuticals company, from 2012 until its merger with Upjohn to form Viatris in 2020. Bresch's career at Mylan spanned more than two decades, during which she held various roles, contributing significantly to the company's growth and facing controversies, notably the pricing of the EpiPen.

Early Life and Education

Heather Bresch grew up in Fairmont, West Virginia. She is the daughter of Joe Manchin, a prominent political figure who has served as the Governor of West Virginia and a U.S. Senator. Bresch earned her undergraduate degree in international relations and political science from West Virginia University (WVU).

Career

Bresch's career at Mylan began in 1992 in the company's basement as a data entry clerk. Over the years, she climbed the corporate ladder, holding various positions within the company, including chief operating officer before becoming CEO. As CEO, Bresch focused on expanding Mylan's global presence and was instrumental in several acquisitions that broadened the company's portfolio of medications.

Controversies

Bresch's tenure at Mylan was not without controversy. One of the most notable was the significant price increase of the EpiPen, an auto-injector used to treat severe allergic reactions. The price hike led to widespread public and political backlash, with Bresch being called to testify before Congress in 2016. Additionally, questions were raised about Bresch's MBA from West Virginia University, leading to an investigation that concluded some of her coursework requirements had been waived.

Personal Life

Details about Bresch's personal life are relatively private. She is known to be an advocate for affordable healthcare and has been involved in various initiatives and discussions related to healthcare policy and drug pricing.

Legacy

Bresch's legacy in the pharmaceutical industry is mixed. On one hand, she is recognized for her role in growing Mylan into a global pharmaceutical giant and for her efforts to increase access to generic medications. On the other hand, her leadership has been marred by controversies that have sparked debates about drug pricing and corporate governance in the pharmaceutical industry.